(Total Views: 474)
Posted On: 03/03/2021 12:25:45 PM
Post# of 148878
Here's what a study is about to fail:
"The companies were informed that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit. The independent Data and Safety Monitoring Board (DSMB) has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. The companies will continue discussions with the NIH about appropriate ways to further assess the potential of VIR-7831 in the hospitalized population as all parties gain a fuller understanding of the still-emerging data. "
https://www.globenewswire.com/news-release/20...ID-19.html
How did the DSMC/DSMB decide on Leronlimab several times?
"The companies were informed that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit. The independent Data and Safety Monitoring Board (DSMB) has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. The companies will continue discussions with the NIH about appropriate ways to further assess the potential of VIR-7831 in the hospitalized population as all parties gain a fuller understanding of the still-emerging data. "
https://www.globenewswire.com/news-release/20...ID-19.html
How did the DSMC/DSMB decide on Leronlimab several times?
(2)
(0)Scroll down for more posts ▼
